How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Arterial Cannula Market
- By Material Type: Polyvinyl Chloride (PVC), Polyurethane, Silicone, Latex
- By Cannula Tip Design: Straight Tip, Curved Tip, Blunt Tip, Beveled Tip
- By Cannula Size (French): 12 Fr, 14 Fr, 16 Fr, 18 Fr, 20 Fr
- By Application: Cardiopulmonary Bypass, Extracorporeal Membrane Oxygenation (ECMO), Hemodialysis, Cardiac Surgery
- By Insertion Technique: Percutaneous, Surgical Cutdown
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Polyvinyl Chloride (PVC) leads By Material Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 13 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 287 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.175 →
- 12 Company Profiles 13 players: SWOT & benchmarking p.183 →
Full report · locked preview
Everything inside the Arterial Cannula Market report
A complete, evidence-based study - 12 chapters and 120 sections covering market size, segmentation across 5 axes, regional analysis and 13 company profiles, forecast to 2033.
Segmentation covered
Material Type 4
Cannula Tip Design 4
Cannula Size (French) 5
Application 4
Insertion Technique 2
Companies profiled
Medtronic
Terumo Corporation
Getinge AB
LivaNova PLC
Sorin Group (now part of LivaNova)
Edwards Lifesciences
Maquet (a Getinge brand)
Nipro Corporation
Hemovent GmbH
C.R. Bard (now part of BD)
Sarns (a Terumo brand)
LivaNova
+1 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
13 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Medtronic
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Terumo Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Getinge AB
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →LivaNova PLC
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Sorin Group (now part of LivaNova)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Edwards Lifesciences
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →Maquet (a Getinge brand)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Nipro Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Hemovent GmbH
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →C.R. Bard (now part of BD)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Sarns (a Terumo brand)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.214 →LivaNova
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.220 →Medos Medizintechnik AG
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$3,688M by 2033 · 5.1% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Polyvinyl Chloride (PVC)46.2
- Polyurethane20.8
- Silicone18.1
- Latex15.0
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$818.6M → $1,201M · 4.9%
Europe$570.6M → $867.3M · 5.4%
Asia Pacific$521.0M → $733.3M · 4.4%
Latin America$322.5M → $492.4M · 5.4%
Middle East and Africa$248.1M → $364.9M · 4.9%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →5.032026
5.042027
5.062028
5.082029
5.082030
5.092031
5.112032
5.112033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Medtronic24.6
- Terumo Corporation21.7
- Getinge AB8.7
- LivaNova PLC5.8
- Sorin Group (now part of LivaNova)7.4
- Edwards Lifesciences3.8
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Material Type24.4%
Cannula Tip Design21.3%
Cannula Size (French)17.5%
Application21.6%
Insertion Technique15.2%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.8
- Europe23.7
- Asia Pacific20.0
- Latin America13.5
- Middle East and Africa10.0
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Medtronic | 87 | 77 | 74 | 89 | 96 | 87 | 85 |
| Terumo Corporation | 69 | 69 | 90 | 81 | 70 | 85 | 77 |
| Getinge AB | 67 | 87 | 76 | 67 | 88 | 80 | 78 |
| LivaNova PLC | 81 | 67 | 76 | 72 | 58 | 68 | 70 |
| Sorin Group (now part of LivaNova) | 69 | 59 | 56 | 64 | 62 | 74 | 64 |
| Edwards Lifesciences | 64 | 47 | 58 | 55 | 50 | 65 | 57 |
| Maquet (a Getinge brand) | 64 | 60 | 53 | 43 | 42 | 57 | 53 |
| Nipro Corporation | 36 | 50 | 41 | 49 | 42 | 35 | 42 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Medtronic
- Terumo Corporation
- Getinge AB
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Medtronic | ✓ | ◐ | ◐ | ◐ | ✓ | ✓ |
| Terumo Corporation | ◐ | − | ✓ | ◐ | ✓ | ✓ |
| Getinge AB | ✓ | ◐ | ◐ | ◐ | ✓ | ◐ |
| LivaNova PLC | ◐ | ◐ | ✓ | ◐ | − | ◐ |
| Sorin Group (now part of LivaNova) | ◐ | − | − | ◐ | ◐ | ✓ |
| Edwards Lifesciences | ◐ | − | ◐ | ◐ | ◐ | − |
| Maquet (a Getinge brand) | ◐ | − | ◐ | − | − | ◐ |
| Nipro Corporation | − | ◐ | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Medtronic85
2Getinge AB78
3Terumo Corporation77
4LivaNova PLC70
5Sorin Group (now part of LivaNova)64
6Edwards Lifesciences57
7Maquet (a Getinge brand)53
8Nipro Corporation42
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
MedtronicGetinge AB
Challenger2
Strong scale, closing on the leaders.
Terumo CorporationLivaNova PLC
Contender2
Focused players with pockets of strength.
Sorin Group (now part of LivaNova)Edwards Lifesciences
Niche2
Specialists in a single segment or region.
Maquet (a Getinge brand)Nipro Corporation
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Material Type in North America, then scale across Arterial Cannula Market — a $385M beachhead inside a $6.39B market.
Beachhead (SOM)$385Mobtainable near-term
Serviceable (SAM)$2.19Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
Polyvinyl Chloride (PVC)
Best fit — highest urgency & budget in Material Type.
Economic buyer77 fit
Polyurethane
Strong fit — clear ROI and a fast path to value.
End user67 fit
Silicone
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Material Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Cannula Tip Design & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Cannula Size (French)
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales41%
Partner / channel29%
Digital / self-serve22%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Material Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Arterial Cannula Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified23%
Evaluation12%
Closed-won5%
$10.0KCAC
$53KLTV
5.3:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Arterial Cannula Market is a durable-growth opportunity — $7.90B by 2033, compounding at 6.5%.
TAM · 2025$4.78Btoday
TAM · 2033$7.90Bforecast
CAGR6.5%2027–2033
Cumulative$56.0Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$7.90BTotal addressable market
SAM$2.85BServiceable available market
SOM$539MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →6.5% CAGR
Demand compounds through 2033, outpacing GDP across Material Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Material Type moving from early to mainstream — durable secular demand.
Consolidation upside
13+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$7.90BLarge & growingTAM by 2033 at 6.5% CAGR
$2.85BServiceable nowreachable with today’s model
$539MBeachhead winobtainable near-term share
13+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$6.16BBear4.2% CAGR
$7.90BBase6.5% CAGR
$10.1BBull8.5% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Cannula Tip Design optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Arterial Cannula Market — a $9.04B market by 2033. Plan: grow share from 10.8% to 17.5%.
Market size · 2033$9.04Btotal addressable
Market CAGR10.2%2027–2033
Target share17.5%from 10.8% today
Revenue ambition$1.58Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.8% | 17.5% | Ahead |
| Revenue | $1.06B | $1.58B | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 29.5% | 41.5% | On track |
| Customer retention | 85.0% | 94.3% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Material Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Cannula Tip Design capability
A defensible second engine — invest in Cannula Tip Design to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Material Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Cannula Tip Design
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $197M capacity & capability investment
- Greenlight bolt-on M&A in Cannula Tip Design
- Authorise North America expansion plan
- Fund R&D program for Material Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossBehind
- Input-cost & supply riskBehind
- Regulatory / policy changeBehind
- Execution & talentBehind
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Arterial Cannula Market conversation — a $973M market you can size, segment and defend in minutes.
Market size · 2033$973Mtotal opportunity
Growth6.6%CAGR to 2033
Addressable buyers1,568+accounts in scope
Typical ROI4.6×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Material Type
Goal Grow share in Material Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.6×return on cost, year one
< 3 mopayback period
$62K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
13+players profiled in this market
Coverage includes
MedtronicTerumo CorporationGetinge ABLivaNova PLCSorin Group (now part of LivaNova)Edwards LifesciencesMaquet (a Getinge brand)Nipro Corporation+5 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Arterial Cannula Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Arterial Cannula Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Arterial Intubation Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportArterial Occluder Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportArteriosclerosis Tester Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportArteriovenous Graft Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportArteriovenous Puncture Outfit Market
Market size, share, segmentation and regional forecast.
$815M market · 2025 base year
View reportArthritis Treatment Drug Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportArthroplasty Procedures Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportArthroscopes and Endoscope Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportArthroscopes Systems Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportArthroscopic Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportArthroscopy And Accessories Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportArthroscopy Columns Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.